Some roads are made by those who walk them first.
33 years ago, when drug discovery was still unfamiliar in Korea, one company chose a path no one else had taken.
They found the molecule, ran the trials, secured the approval, and brought it to market themselves in the world’s most demanding pharmaceutical market.
Every step revealed a wall.
Every wall became an experience.
And every experience laid the groundwork.
The proof is already here.
Bold research.
Bolder growth.
Building a sustainable future on our own.
The first Korean biopharma to do so.
And still, the only one.
That success is embodied in our treatment, changing lives around the world.
A normal day may mean little to most people.
To someone, it can mean everything.
Our innovative treatment, present in five continents and 305,000 patients who woke up to a different day.
We do not count them as numbers.
We count them as days returned.
Bringing a drug to market is not the finish line.
For us, it is the starting line.
We are moving beyond CNS toward unconquered areas.
At the leading edge — radiopharmaceutical therapy.
Moving through the bloodstream, seeking and binding to cancer cells selectively, and then destroying them from within with the energy of alpha particles.
Precise.
Targeted.
Uncompromising.
Into territory once thought impenetrable — targeted protein degradation.
A platform that reaches proteins previously considered undruggable, recruiting the cell’s destruction machinery and completely dismantling the target.
In CNS, we're not starting over; we're going deeper.
From areas we have explored to those we have never been.
Beyond managing the symptoms toward addressing the root causes of the disease.
Three directions.
One goal.
To reach the patients for whom medicine has yet to provide an answer.
Headquarters leading global R&D and network.
The driving force of innovation with AI.
SK Biopharmaceuticals.
From global clinical development to every regulatory milestone and quality assurance.
Bringing innovation to the patients.
SK Life Science.
Opening new possibilities to treat diseases once thought beyond reach.
SK Life Science Labs.
Connecting Asia to bring innovation to reach more patients.
SK Bio-Pharm Tech.
Inside the lab, AI changes how we find the next drug.
Predictive models.
Human-AI collaboration.
Faster and sharper.
Fewer dead ends.
Across the operation, AI changes how we execute.
Forecasting, quality optimization, end-to-end visibility across the entire value chain.
And beyond treatment, into the patient's daily life.
Continuous monitoring.
Real-world data.
Precision at scale.
AI-enabled patient insights designed to support care beyond treatment.
AI embedded in every moment of how we work.
AI-Native Biopharma.
Many companies are well run.
Few have a mission this clear.
As the only Korean biotech recording expanding operating profits, our success directly ignites bolder R&D investments.
A virtuous cycle where today's growth secures tomorrow's breakthroughs.
Many companies call “global big biotech” an ambition.
For us, it is a blueprint.
But the structure is not the mission.
Our mission is so the people we love stop suffering.
So someone can live life on their own terms again.
So the days they thought they had lost can come back.
Each life is why we research, why we take risks, and why we should grow.
We have the power to make it happen.
Research from the East.
Opportunities in the West.
We didn’t choose one; we connected them.
There's a kind of focus that comes from desire to push further.
The relentless drive to move fast, aim high, and never let go of the goal.
And there's a kind of wisdom that comes from experience.
Decades of clinical know-how, regulatory depth, and the world's most demanding market with a proven track record of success.
We don't see these as opposites.
We see them as the two sides of a bridge.
Asia's speed, ambition, and tenacity.
The West's expertise, access, and proven ground.
SK Biopharmaceuticals connects both not through ambition, but through experience.
We keep moving into territory no one has mapped yet.
We are the East-West Bridge.
We are SK Biopharmaceuticals.